tiprankstipranks
TSVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsTSVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
2seventy bio Halts KarMMa-9 Study, Forecasts Strong Abecma Sales
Premium
Company Announcements
2seventy bio Halts KarMMa-9 Study, Forecasts Strong Abecma Sales
5M ago
2seventy Bio to discontinue enrollment in Phase 3 KarMMa-9 study of Abecma
Premium
The Fly
2seventy Bio to discontinue enrollment in Phase 3 KarMMa-9 study of Abecma
5M ago
2seventy bio Strikes Strategic Gene Therapy Deal with Novo Nordisk
PremiumCompany Announcements2seventy bio Strikes Strategic Gene Therapy Deal with Novo Nordisk
8M ago
2seventy Bio announces sale of Hemophilia A candidate for up to $40M
Premium
The Fly
2seventy Bio announces sale of Hemophilia A candidate for up to $40M
8M ago
2seventy bio’s Board Elections and Financial Oversight Update
Premium
Company Announcements
2seventy bio’s Board Elections and Financial Oversight Update
8M ago
2seventy Bio price target raised to $12 from $9 at Citi
PremiumThe Fly2seventy Bio price target raised to $12 from $9 at Citi
11M ago
2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma
Premium
Company Announcements
2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma
11M ago
Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
Premium
The Fly
Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100